BioAtla, Inc.
BCAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.16 | 4.21 | -0.04 |
| FCF Yield | -250.50% | -88.58% | -28.24% | -9.31% |
| EV / EBITDA | 0.27 | -0.07 | -1.04 | -4.66 |
| Quality | ||||
| ROIC | -190.98% | -139.54% | -52.98% | -40.86% |
| Gross Margin | 91.59% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 1.03 | 0.84 | 0.85 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -63.64% |
| Free Cash Flow Growth | 30.91% | -14.80% | -43.63% | -70.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.66 | 0.89 | 2.01 | 2.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -32,146.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -750.52 | -1,141.63 | -1,288.00 | 0.00 |